RxDoctor Payments Data

Joanna Branum, MD

General Practice · Greeley, CONPI 1033184957

Payments from drug & device makers

$1,497in general payments, 2019–2025

Across 46 payments — averaging $32.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$375
  • AbbVie$339
  • AstraZeneca$164
  • Lilly USA, LLC$98
  • Biohaven Pharmaceuticals, Inc.$82
  • Biohaven Pharmaceutical Holding Company Ltd.$58
  • plus $380 from 15 others

What the payments were for

  • Food & beverage$1,497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,497 in reported general payments places this provider in the 85th percentile of 1,802 general practice providers in Colorado.

See all general practice providers in Colorado

Medicare billing

Part B allowed, 2024
$7,060
Medicare patients
23
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$36,667
MounjaroTirzepatide16$19,616
OzempicSemaglutide11$18,576
Tramadol Hcl41$1,487
Levothyroxine Sodium157$1,461
Rosuvastatin Calcium137$1,042
Omeprazole71$669
Albuterol Sulfate HfaAlbuterol Sulfate21$660
Losartan Potassium91$647
Lisinopril103$559
Atorvastatin Calcium62$557
Gabapentin31$546
Trazodone Hcl43$483
Escitalopram Oxalate30$392
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$36,66728 claims
Lilly USA, LLCMounjaro$98$19,61616 claims
Novo NordiskOzempic$44$18,57611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,802 general practice providers in Colorado.

Other general practice in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →